Why Most Cost-Cutting Advice Fails Employers and Plan Sponsors Every benefits consultant in America will tell you the same thing: […]

Pfizer killed torcetrapib in 2006 after spending $800 million on a cholesterol drug that raised blood pressure instead of lowering

The generic drug industry, often relegated to the background of high-profile blockbuster headlines and breakthrough therapy announcements, is not merely

How Abandoned ANDA Litigation Patents Predict Weaker Enforcement The Most Underrated Signal in Generic Drug Intelligence When a brand pharmaceutical

The pharmaceutical supply chain is a complex, multi-tiered network that historically has been optimized for efficiency and cost reduction above

Investors and executives often treat the expiration of a composition-of-matter patent as the singular moment of truth in a drug’s

The strategic landscape of the modern pharmaceutical and biotechnology industries is bifurcated by two distinct regulatory and legal architectures that

The regulatory framework of the United States pharmaceutical industry is governed by a complex interplay of scientific evaluation, legislative compromise,

The pharmaceutical landscape in the United States is currently defined by a paradox: a system designed to foster innovation has